Skip to main content
OpenTrials
Completed

NCT Number: NCT05661370

App Teaches Doctors to Diagnose Skin Cancer

This study aimed to examine if self-paced learning with a novel digital patient-case-based educational platform can increase primary care physicians' diagnostic accuracy of malignant and benign skin lesions on both the level of benign/malignant and the diagnosis level. Secondarily the study aimed to investigate the time spent in reaching this change in proficiency.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Melanoma (Skin) Carcinoma Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year–120 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AISC Research Fascility

Copenhagen, Danmark, 2700, Denmark

About this study

Participants were given a questionnaire and an initial Skin Cancer Multiple Choice-Questionnaire (MCQ) to test their diagnostic skills regardining skin and mole cancer and the most common differential diagnoses.

Participants in the Intervention group was then given access to an educational mobile application (App) for 8 days and asked to diagnose 500 patient cases. The participants did so at their own leisure and time.

After 8 days they were asked to abstain from using the App for another 8 days (wash out period) and were then given a Final Skin Cancer Multiple Choice-Questionnaire (MCQ).

Participants of the control group received no intervention nor education during the 16 days of waiting before they took the final Skin Cancer Multiple Choice-Questionnaire.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary Care Physician who works in General Practice

Exclusion criteria

-

Treatment and study plan

DermLoop Learn

Other

Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.

Primary outcomes

  1. Multiple-Choice Questionnaire (MCQ) Score

    Time frame: Before and immediately after intervention (On average 19 days after enrollment)

    Participants are given a test before and after the intervention using a skin cancer MCQ test with 12 digital-patient cases. A higher score means better diagnostic proficiency. The primary outcome is the change of this score.

Secondary outcomes

  1. Diagnostic proficiencies

    Time frame: During the 8 days of access to the educational mobile application.

    Sensitivity, Specificity and Positive Predictive Value of the participants in the intervention group, calculated on their cases seen in the educational mobile application.

  2. Time spend

    Time frame: During the 8 days of access to the educational mobile application.

    The Dermloop Learn app tracks how much time each user spends quizzing and reading.

Sponsors and collaborators

Lead sponsor

Herlev Hospital

Other

Registry information

Official study title

Improving Diagnostic Accuracy in Skin Cancer Diagnostics Using Educational Mobile App: a Randomized Controlled Study

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 22, 2022
Registry last updated
Jul 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.